GSK Appoints Minnie Ke as Vice President and Head of Medical Affairs for China

July 7，According to pharmaceutical representatives,GSK Vice President and General Manager of China, Sherman Yu (余慧明), and GSKVice President,Mark Toms, Head of Medical Affairs, GSK Greater China and Intercontinental (GCI), Announces to Employees，Yuxiong Ke (Minnie Ke will join GSK as Vice President and Head of China Medical Affairs, effective immediately.

Yu Xiong Ke graduated from the Immunology program at Temple University in the United States and Fudan University in Shanghai, andOwnFranceNICE University DBA in Management. She has extensive industry experience both pre- and post-market, with responsibility across multiple disease areas, as well as management experience in a Medical Excellence team. With over 16 years of service, she has successfully collaborated with the China National Medical Products Administration (NMPA) to introduce several rare disease products.

After graduating in 2004, she joined a pharmaceutical company, starting as a Medical Advisor at Merck. She subsequently served as the Brand Head of the Immunology Group at Novartis China and as the Head of Medical Affairs at Shire China.Its earlyJoined Merck's clinical development position in the United States, successfully participated in and completed productPhase 1b and Phase IIb clinical studies successfully supported the product's U.S. market launch, after which I returned to MSD China to begin overseeing post-marketing activities for the Infectious Diseases Medical Department.

2018Afterwards, she transitioned to the clinical development field, successively holding positions such as Vice President of Clinical Research and Medical Affairs at CANbridge, Head of Product Development at Bristol-Myers Squibb China R&D, and Head of Product Strategy at GenSci.

Currently,GSK is deepening its presence in the Chinese market with unprecedented intensity., whose corporate mission is "to revolutionize healthcare with groundbreaking vaccines and medicines, overcoming diseases together," is reshaping the future landscape of China's health industry.

This YearIn April, GSK established a new Chief Operating Officer position in the Chinese market., to be held by Maurizio Borgatta, then Vice President of GSK and General Manager of Korea, who will be based in Shanghai and join the leadership team of GlaxoSmithKline China. This position is newly established.Aiming to empower the efficient advancement of the "Medical-Prevention Integration" strategy by expanding GSK's management team in China.

In June, GSK carried out another major organizational restructuring.Integrate the two major regions of Emerging Markets (EM) and Greater China and Intercontinental (GCI)The newly integrated international region is led by Mike Crichton, Senior Vice President of GSK Greater China and Intercontinental Region (GSK GCI).

GSK stated that the two major regions are important markets for the company, and the integration is forBetter focus resources on product launches and pipeline R&D, enhance the flexibility of the entire market, expand the application of technology and artificial intelligence to empower teams, and drive the next phase of growth.. It is hoped that byTo be completed by the end of this year。

According toGeneral Manager of GSK ChinaYu Huiming said,GSK ChinaOver 90%The drug research has joined the global synchronized R&D, and currently, the company hasMore than 30 innovative pipeline projectsCarried out in China, of which approximately1/4 of the products in the R&D pipeline are vaccines.; In the next five years,ExpectedYesMore than 20 new products or new indicationsApproved for marketing in China, including the first globally approved and clinically approved in ChinaRespiratory Syncytial Virus (RSV) Vaccine, andThe world's first antisense oligonucleotide (ASO) drug with the potential to achieve "functional cure" for chronic hepatitis B。

In summary,GSK China is taking strategic certainty as the guiding principle, strengthening its product pipeline, expanding its management team, and focusing on the strategic goal of "integrating medical treatment and prevention, with prevention first"."Planning strategic moves to elevate the Chinese market to become GSK's second-largest global market by 2031"，InBenefit400 million Chinese people.

References:

[1] Yu Xiong Ke joins GSK China, new president of Peking University Pharmaceutical confirmed! Medical Representative. July 7, 2025.

[2] Personnel Appointment! Yuxiong Ke joins GSK. chasen shallow view. July 8, 2025.

[3] GSK, Structural Adjustment. Pharmaceutical Representative. June 13, 2025.

[4] Yu Huiming, Vice President of GSK and General Manager of China: The "Underlying Logic" of GSK China's Strategic Upgrade — Integration of Medical Treatment and Prevention, Synergy Beyond Vaccines and Drugs. 21st Century Economic Report. April 30, 2025.

[5] Yu Huiming, Vice President of GSK and General Manager of China: Feeling the Steadfastness of China's Economy and the Vitality of Progress | "Foreign Eyes" on the Two Sessions. International Financial News. March 7, 2025.